In a significant stride for interventional cardiology, Venus Medtech has officially announced the completion of patient enrollment for its confirmatory clinical trial of the Venus-PowerX transcatheter aortic valve replacement (TAVR) system in China. This milestone marks a pivotal moment in the company’s mission to transition structural heart interventions from "partially controllable" to "fully controllable" procedures, potentially setting a new gold standard for the treatment of severe aortic stenosis.
The device, distinguished as the world’s first self-expanding dry-valve TAVR system, represents a leap forward in mechanical design and procedural safety. By finalizing enrollment for the multi-centre, prospective, objective performance criterion (OPC), single-arm study—known as the PREVAILS trial—Venus Medtech has moved one step closer to securing critical regulatory approvals in two of the world’s most rigorous markets: China and Europe.
The Venus-PowerX: Redefining Structural Heart Intervention
Severe aortic stenosis is a debilitating condition characterized by the narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body. For decades, surgical aortic valve replacement (SAVR) was the standard of care. However, the advent of TAVR technology has revolutionized the field, allowing surgeons to replace diseased valves through minimally invasive catheter-based approaches.
The Venus-PowerX system enters this competitive landscape with a unique value proposition: it is a "dry-valve" technology. Unlike conventional TAVR valves, which are typically stored in glutaraldehyde solutions, the Venus-PowerX is processed to be stored in a dry state. This innovation significantly simplifies clinical workflows, reduces preparation time in the operating room, and enhances shelf-life and logistics.
Perhaps more importantly, the device features advanced retrieval technology. The Venus-PowerX allows for full release and complete retrieval after total deployment. This level of control is a major clinical advantage, as it provides cardiologists with the "safety net" to reposition or retrieve the valve if it is not perfectly placed during the initial deployment phase. This capability significantly reduces the risk of paravalvular leaks and the potential need for permanent pacemaker implantation—two of the most common complications associated with older generation TAVR devices.
Chronology of Development and Global Expansion
The journey of the Venus-PowerX has been marked by strategic research and development and a phased international rollout.
- Initial R&D Phase: Venus Medtech, leveraging its international R&D centers in China, Israel, and the US, conceptualized the Venus-PowerX to address the limitations of existing TAVR systems, specifically focusing on the precision of valve positioning.
- Early Regulatory Success: Before embarking on the massive PREVAILS study in China, Venus Medtech sought and achieved regulatory clearances in select South American markets. The device has already been successfully launched and is currently available for commercial use in Argentina, Chile, and Venezuela.
- The PREVAILS Study Commencement: Following positive early clinical experiences in Latin America, the company initiated the PREVAILS study in China. This trial was designed specifically to provide the high-quality, objective data required by the National Medical Products Administration (NMPA) and the European regulatory bodies for CE marking.
- Current Milestone: The conclusion of enrollment in the PREVAILS study, as announced in late July 2026, signals that the clinical phase is nearing its end, shifting the focus toward data analysis and the submission of regulatory dossiers.
Supporting Data and Clinical Evidence
The PREVAILS study is a multi-centre, prospective, single-arm trial that utilizes an objective performance criterion (OPC). By using an OPC, the study aims to compare the clinical outcomes of Venus-PowerX patients against historical benchmarks and established safety standards in the TAVR field.
The primary endpoints of the study are comprehensive, focusing on:
- Safety: Incidence of all-cause mortality, stroke, and life-threatening bleeding at 30 days and one year post-procedure.
- Efficacy: Hemodynamic performance of the valve, measured by the reduction in the mean transvalvular pressure gradient and the absence of moderate-to-severe paravalvular regurgitation.
- Device Performance: Technical success rate, defined by the ability to achieve successful vascular access, delivery, and deployment of the device, alongside the retrieval functionality where necessary.
While the full dataset remains under analysis, real-world data from the deployments in Argentina and Chile have provided the company with an encouraging foundation. These "real-world" cohorts have highlighted the device’s ease of use and the performance of the self-expanding frame in varying anatomical complexities. By incorporating this data alongside the PREVAILS study results, Venus Medtech intends to present a robust evidence package to regulators, demonstrating that the device is not only safe but provides superior control for the operator.
Official Perspectives: The Vision for "Fully Controllable" Heart Care
Ma Renzheng, Chief Technology Officer at Venus Medtech, emphasized the significance of this milestone, framing it as a shift in the philosophy of structural heart surgery.
"The successful completion of enrolment in the Venus-PowerX confirmatory trial positions this device as a significant addition to our TAVR portfolio," Renzheng stated. "We are committed to offering patients with severe aortic stenosis a more precise, safer, and more controllable treatment option. Our ultimate goal is to advance structural heart intervention from ‘partially controllable’ to ‘fully controllable’ at every step of the procedure."
This shift toward "full control" is aimed at addressing the anxiety that many surgeons face when deploying a permanent implant. In the current standard of TAVR, once a valve is deployed, it is often difficult or impossible to adjust. The Venus-PowerX’s ability to be retrieved after total deployment effectively lowers the "point of no return," empowering surgeons to achieve optimal anatomical alignment and long-term hemodynamic stability.
Broader Implications for the TAVR Market
The implications of the Venus-PowerX’s success extend beyond a single company. The global TAVR market is increasingly moving toward systems that emphasize ease of use, durability, and a reduction in post-procedural complications.
1. Market Penetration in China and Europe
China represents one of the fastest-growing TAVR markets in the world, driven by an aging population and increasing access to advanced healthcare. Success in the NMPA approval process will solidify Venus Medtech’s position as a domestic leader capable of competing with global giants. Simultaneously, achieving the CE mark in Europe will allow the company to enter the highly competitive European market, where clinical evidence is the primary driver of hospital adoption.
2. The "Dry-Valve" Competitive Advantage
The dry-valve technology offers logistical benefits that could disrupt the supply chain of traditional TAVR providers. Hospitals, constantly looking to optimize their inventory management and reduce the time spent on device preparation, may find the Venus-PowerX more attractive than liquid-stored alternatives.
3. A Broader Portfolio Strategy
The Venus-PowerX study is only one part of a larger ecosystem of innovation at Venus Medtech. The company’s ongoing work with the VenusP-Valve, which recently saw its first implantation in the US as part of the PROTEUS investigational device exemption (IDE) study, indicates that the company is building a comprehensive suite of structural heart solutions. By diversifying its portfolio across aortic and pulmonary valve technologies, Venus Medtech is positioning itself as a vertically integrated powerhouse in cardiovascular medicine.
Future Outlook and Next Steps
As the medical community awaits the publication of the PREVAILS study results, the industry will be watching for several key indicators: the rate of permanent pacemaker implantation, the incidence of residual paravalvular leak, and the procedural time compared to current market-leading valves.
Venus Medtech’s ability to navigate the regulatory landscape in China and Europe will serve as a barometer for the company’s maturity. If the trial data holds up to the rigorous standards of the European Medicines Agency (EMA) and the NMPA, the Venus-PowerX could reach the market by late 2027 or early 2028.
For patients suffering from severe aortic stenosis, the promise of a "fully controllable" valve means more than just a successful surgery—it means a higher probability of long-term health and a lower likelihood of follow-up interventions. As the company transitions from the trial phase to the regulatory review phase, the focus will undoubtedly shift to scaling production and preparing for the massive logistical requirements of a global launch.
In conclusion, the completion of the PREVAILS trial enrollment is a testament to Venus Medtech’s clinical ambition. By prioritizing surgeon control and procedural safety, the company is not merely iterating on existing technology; it is attempting to define the next generation of structural heart care. Whether the Venus-PowerX becomes the new industry standard will depend on the final data, but the path toward a more "controllable" future for heart patients is becoming increasingly clear.
About the Author
